Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-30T20:16:35.084Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine in geriatric psychiatry: the need for robust contemporary clinical research to ascertain indications, risks, and benefits in vivo

Published online by Cambridge University Press:  03 June 2021

Jonathan D. Artz  and
James A. Bourgeois
Jonathan D. Artz
Affiliation:
Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, College of Medicine, Texas A&M University Health Science Center, 2401 South 31st Street, Temple, TX76508, USA
James A. Bourgeois*
Affiliation:
Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, College of Medicine, Texas A&M University Health Science Center, 2401 South 31st Street, Temple, TX76508, USA
*
Email: james.bourgeois@bswhealth.org
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
International Psychogeriatrics , Volume 34 , Special Issue 10: Issue Theme: Pharmacotherapy for Serious Neuropsychiatric Disorders , October 2022 , pp. 857 - 859
Copyright
© International Psychogeriatric Association 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Das, A. et al. (2020). Delirium on clozapine: a tale of friend turned foe-A case report. The International Journal of Psychiatry in Medicine, 009121742097282. doi: 10.1177/0091217420972827.CrossRefGoogle Scholar
Gareri, P. et al. (2008). The safety of clozapine in the elderly. Expert Opinion on Drug Safety, 7, 525–538. doi: 10.1517/14740338.7.5.525.CrossRefGoogle ScholarPubMed
Kane, J. M. et al. (1989). Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial. Psychopharmacology, 99(1 Supplement), 60–63. doi: 10.1007/BF00442561.CrossRefGoogle Scholar
Meltzer, H. Y. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry, 60(1), 82–91. doi: 10.1001/archpsyc.60.1.82.CrossRefGoogle Scholar
Renzenbrink, M. and Wand, A. (2020). A systematic review of clozapine’s effectiveness for primary psychotic and bipolar disorders in older adults. International Psychogeriatrics. doi: 10.1017/S1041610220004172.CrossRefGoogle Scholar
Sajatovic, M. et al. (1998). Clozapine therapy for older veterans. Psychiatric Services, 49, 340–344. doi: 10.1176/ps.49.3.340.CrossRefGoogle ScholarPubMed
Samudra, N. et al. (2016). Psychosis in Parkinson disease: a review of etiology, phenomenology, and management. Drugs Aging, 33, 855–863. doi: 10.1007/s40266-016-0416-8.CrossRefGoogle ScholarPubMed
Young, C. R., Bowers, M. B. and Mazure, C. M. (1998). Management of the adverse effects of clozapine. Schizophrenia Bulletin, 24, 381–390. doi: 10.1093/oxfordjournals.schbul.a033333.CrossRefGoogle ScholarPubMed